EMA Considers Adolescent Booster-Dose Application for Comirnaty

Article

EMA has started its evaluation of an application for the use of a booster dose of Comirnaty in adolescents aged 12–15 years.

The European Medicines Agency (EMA) has started its evaluation of an application for the use of a booster dose of BioNTech/Pfizer’s COVID-19 vaccine, Comirnaty, in adolescents aged 12–15 years.

As reported in a Feb. 8, 2022 press release, EMA’s Committee for Medicinal Products for Human Use (CHMP) will perform an accelerated assessment of data that has been submitted by the company responsible for marketing Comirnaty. The data that has been submitted includes real-world evidence from Israel.

Currently, the booster doses of Comirnaty are approved to be administered in patients aged 18 years and older. An application for a booster dose of the vaccines in patients aged 16–17 years is also ongoing.

EMA will provide further information and updates on the evaluation in due course.

Source: EMA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes